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Abstract  
There is little data on direct medical costs and how to overcome the shock introduced by the novel Coronavirus 
(COVID-19) which emerged in Wuhan, China. The aim of this report is to present the methodology of an 
observational study for analyzing the resource utilization and direct medical costs of hospitalization. A 
multicenter retrospective observational study will be conducted on hospitalized patients with COVID-19 in 
selected hospitals of Tehran University Medical Sciences from February to June 2020. Cost calculations will be 
based on micro-costing approaches according to the health insurance perspective. Demographic, clinical, and 
cost data for the aforementioned patients will be collected through reviews of medical and financial records 
using a self-made checklist categorized in three parts. The first part consists of demographic characteristics, 
the second part includes clinical information (e.g., symptoms, comorbidities, and complications), and the third 
part consists of resource utilization and cost data. Descriptive statistics (means, frequencies, percentages, and 
95% confidence intervals) will be used to report data. With this report we sought to provide a valuable 
framework for estimating the direct medical costs of COVID-19 for hospitalized-patients basis on the severity 
of presentation. This will be the core for an assessment of the economic burden of COVID-19 in different 
presentations of the disease. 
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INTRODUCTION
The novel coronavirus (COVID-19) has had a major 
effect on general health. First appearing in Wuhan, 
China in December 2019, COVID-19 has now 
affected 212 countries and territories around the 
world. People throughout the world are at risk for 
this highly contagious disease. Some under-
developed countries are combatting the lack of 
necessary items for hygienic protection and 
inadequate facilities for disinfection. Evaluating the 
exact need for soap, disinfectants, facial masks, and 
shields is difficult. Since COVID-19 became 
pandemic, it has caused huge economic depression 
all around the world, even occurring in 15 rich 
developed countries (1-3). The economic shock is 
evident, and recovery will need a long time. Most 
patients have mild symptoms; however, severe 
cases progress to acute respiratory distress 
syndrome (ARDS). The rate of severe presentation 
of this disease as reported by previous studies is 
high in patients over the age of 60 and in those with 
co-existing comorbidities such as cardiovascular 
disease (4, 5). The Centers for Disease Control and 
Prevention (CDC) reported that the hospitalization 
rate for COVID-19 was 4.6 per 100,000 people, and 
the rate increased with age. Hospitalization rates 
were highest (13.8 per 100,000 population) among 
adults aged ≥65 years (3). World meters have 
reported that the mortality rate in all age groups 
was 1.8-3.4% and also increased with age. The 
highest rate was in those over 85 years of age 
(10.4-27.3%) followed by those aged 75–84 years 
(4.3-10.5%) (1). There is little data on the direct 
medical costs of COVID-19 and how to overcome 
the challenge of shock it has contributed to the 
world. The report aims to present a brief reliable 
concise and practical protocol for estimating the 
economic impact of the hospitalization of patients 
with COVID-19 and outline the necessary and 
general features to be considered in estimating 
such costs in order to help healthcare policy-
makers. 
Methods 
Study design and setting 
The primary objective of the study is to estimate 
the average direct costs of COVID-19 
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hospitalization in Tehran, Iran by examining 
selected hospitals affiliated to Tehran University 
Medical Sciences (TUMS). The secondary 
objectives are to explore the cost of COVID-19 
complications in different patient groups, identify 
the influence of patient characteristics on cost and 
resource utilization, and to explore the variation in 
costs across hospitals. The study will be designed, 
arranged, and directed by a scientific core 
consisting of a cardiologist, an epidemiologist, and 
a health economics specialist. Approval for this 
study has been obtained from TUMS, with the code 
IR.TUMS.VCR.REC.1399.242. This study will 
conduct a multicenter retrospective observational 
study on confirmed COVID-19 patients 
hospitalized in three university hospitals (referral 
centers of COVID-19 during the pandemic) in the 
time period February to June 2020. All hospitalized 
patients with clinically diagnosed COVID-19 based 
on the World Health Organization interim guidance 
will be included (6). Cases will be confirmed by 
either chest computed tomography (CT) scan or 
reverse-transcription polymerase chain reaction 
testing (RT-PCR). The estimated minimum number 
of participants to achieve the study’s primary and 
secondary objectives is around 300 patients. 
Cost calculation 
Cost calculations will be based on micro-costing 
approaches from the health insurance perspective. 
The direct medical costs will be calculated by 
multiplying the total amount of each medical 
resource by the unit cost. The total cost of an 
admission will be calculated as the sum of the costs 
of emergency department, hospital ward, and ICU 
stays, laboratory and other diagnostic tests, 
procedures, and medication. Demographic, clinical, 
and cost data for participating patients will be 
collected by reviewing medical and financial 
records and using a self-made checklist categorized 
in three parts (Appendix 1). The first part consists 
of items regarding demographic characteristics 
(e.g., age, gender, health status, nationality, 
employment, and geographic region); the second 
part is comprised of items on clinical information 
(e.g., symptoms such as fever, cough, fatigue, 
dyspnea), comorbidities (e.g., hypertension, 
diabetes, cardiovascular disease, and respiratory 
system disease), and complications (e.g., acute 
respiratory distress syndrome, cardiovascular 
complications, acute liver injury, septic shock, 
disseminated intravascular coagulation, acute 
kidney injury, and death). Complementary data 
regarding resource utilization and cost data will be 
collected in the third part of the checklist, which 
consists of items regarding length of hospital 
and/or intensive care unit (ICU) stays, days on 
mechanical ventilation days, and costs for 
emergency department, general ward and/or ICU 
admissions, isolation room, antibiotic and/or 
antiviral treatments (e.g., oseltamivir, hydroxy-
chloroquine, lopinavir–ritonavir, ribavirin, 
clindamycin, and meropenem), and diagnostic and 
laboratory tests (e.g., chest x-ray and spiral chest 
computed tomography scans, cardiac biomarkers, 
electrocardiograms, and liver function tests). The 
estimated costs will be combined with 
demographic and clinical data and COVID-19 
outcomes to explore determinants of the cost of 
COVID-19 and variations in costs across hospitals. 
All costs presented in Iranian Rials (IRR) and will 
be converted to US dollars (official price of 2020).  
Measures and outcomes 
This study will analyze the economic burden of 
COVID-19 in hospitalized patients by age, gender, 
and comorbidities by investigating the following 
outcomes: hospitalization rates, length of hospital 
stays (LOS), mechanical ventilation days, 
complications including death, and costs 
(inpatient, outpatient and total costs) by hospital. 
Finally, a 3-week follow-up will be done for all 
patients, and the data on the amount of time it takes 
a patient to return to work, clinical results, and 
costs for further visits will be collected. 
Discussion 
This study will analyze the resource utilization and 
direct medical costs of hospitalization for a large 
cohort of confirmed COVID-19 patients in Iran. 
Using hospital billing data and patient medical 
records, we seek to fully illustrate the resources 
utilized in caring for hospitalized patients with 
COVID-19 and to identify factors associated with 
higher inpatient costs. The Al-Ruthia study 
conducted in Saudi Arabia evaluated confirmed 
patients of the Middle East respiratory syndrome 
coronavirus (MERS-CoV) and calculated the mean 
direct medical cost to be 19.923 ± 12.947 US $ (7). 
Since ARDS is the most common final presentation 
in patients who require hospitalization in an 
intensive care unit, it is highly recommended to 
profoundly increase the number of intensive care 
unit (ICU) beds (8). In a study by Murray, profound 
increases in hospital and ICU beds and in ventilator 
usage were predicted as the impact of COVID-19 (9). 
The most frequent hospital costs included hospital 
stay, diagnostic and laboratory costs, medications 
including antiviral treatment and antibiotics, and 
the cost for other admissions. To the best of our 
knowledge, no previous economic study has 
estimated the cost of COVID-19 hospitalizations in 
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Iran. It could be suggested that prioritizing 
preventive strategies and immunization 
procedures may potentially be cost-saving. The 
results of the present study could be useful to 
economic evaluations of COVID-19. Moreover, the 
results may be applied as long-term strategies for 
the management of resource utilization, especially 
for ICU beds, ventilator use, and a temporary 
increase in hospital capacities to meet the excess 
demand in the COVID-19 pandemic era. 
CONCLUSIONS 
With this report we seek to provide a valuable 
framework for estimating the direct medical costs 
of COVID-19 for hospitalized patients with either 
severe or mild patterns of presentation. However, 
it should be kept in mind that there is no 
documented treatment or management strategy 
for these patients, and indeed, the costs will differ 
based on the defined approach to the medical 
treatment strategy. This will be the basis for an 
assessment of the economic burden of different 
presentations of the COVID-19 disease.  
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Appendix 1: The checklist for calculating direct medical cost for COVID-19 patients in TUMS selected hospitals 
Hospital stays 
 
Length of stay (LOS), day 
ISO-Room 
ICU 
Personal protective equipment 
Health care workers fee 
Diagnostic and laboratory tests CBC, Diff, blood group 
CRP 
AST, ALT 
BNP if myocarditis suspected 
Hb-A1C if diabetic 
CPK if myocarditis suspected 
LDH if myocarditis suspected 
Echocardiography if myocarditis suspected 
Chest X-ray 
Spiral chest CT scan 
Cardiac enzymes + ECG 
Renal function test (BUN, Cr, Na, K) 
Serum albumin 
Blood culture*2 if sepsis 
Throat swab culture test 
AFB Test 
ABG, if intubated 
PT, PTT, D-Dimer 
Antibiotics and antiviral Hydroxychloroquine 
Ribavirin 
Lopinavir–Ritonavir 
Interferon-α2 
Oseltamivir 
Atazanavir 
NSAID 
Corticosteroid 
Vancomycin 
Meropenem 
Tazocin 
Azithromycin 
Clindamycin 
Ceftriaxone 
Other medications Paracetamol  
Ascorbic acid 
Cost in other centers Hospital costs 
Diagnostic and laboratory tests 
Medications 
Productivity losses of patient and family members   
LOS: length of stay; ISO-Room: isolation room; ICU: intensive care unit; ECG: electrocardiogram; LFT: Liver function tests; ALT: alanine 
aminotransferase; AST: aspartate aminotransferase; PT: prothrombin time; PTT: partial thrombin time; ABG: arterial blood gas; AFB: 
acid-fast bacillus; BNP: brain natriuretic peptide; BUN: blood urea nitrogen; Cr: serum creatinine; CPK: creatine phosphokinase; LDH: 
lactate dehydrogenase; NSAID: nonsteroidal anti-inflammatory drug; CRP: C-reactive protein 
